Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
KX2-391 Mesylate Chemical Structure
|Product name: KX2-391 Mesylate|
|Cat. No.: HY-10340B|
is a synthetic, orally bioavailable inhibitor of Src kinase and tubulin polymerization, with IC50 of 20 nM for Scr kinase autophosphorylation.
IC50: 20 nM (Scr kinase)
in vitro: KX2-391 has been shown to potently inhibit Src-catalyzed trans-phosphorylation of focal adhesion kinase (FAK), Shc, paxillin, and Src kinase autophosphorylation with an IC50 of approximately 20 nM. It also induces p53 expression and stimulates caspase-3 and PARP cleavage in vitro, leading to tumor cell apoptosis. KX2-391 is potent against a broad range of solid tumor cell types as well as many leukemia subtypes, including those resistant to imatinib and/or dasatinib. It is highly selective without effects on PDGFR, EGFR, JAK1, JAK2, Lck and ZAP70. KX2-391 targets the substrate binding pocket of Src and had more broad spectrum activity and higher potency than dasatinib.
in vovo: KX2-391 demonstrates potent antineoplastic activity across a wide spectrum of tumor cell lines (including several prostate cancer cell lines) and inhibits primary tumor growth as well as metastasis in an orthotopic prostate cancer mouse model.
|M.Wt||527.63||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO: ≥ 57 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||1.8953 mL||9.4763 mL||18.9527 mL|
|5 mM||0.3791 mL||1.8953 mL||3.7905 mL|
|10 mM||0.1895 mL||0.9476 mL||1.8953 mL|
. "Naing A, et al. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs.?2013 Aug;31(4):967-73. "
. "Antonarakis ES, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol.?2013 Apr;71(4):883-92 "
10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.
10-Oxo Docetaxel(Docetaxel Impurity) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.
2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 (plusmn) 0.11 (mu)M for the inhibition of BPAEC migration.
4(acute)-Demethylepipodophyllotoxin(4(acute)-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.
7-Epi-10-oxo-docetaxel (Docetaxel Impurity D) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).
7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.
7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.
A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.
ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 (mu)M in neuroblastoma and non-neuroblastoma cell lines, respectively.
AMG-47a is a potent inhibitor of Lck and T cell proliferation; exhibits anti-inflammatory activity (ED50 = 11 mg/kg) in the anti-CD3 induced production of IL-2 in mice.